Articles by David Swoboda, MD
Is ESA use and performance in the academic setting reflective of real-world MDS practice? Our expert panel discusses.
The panel discusses how to best implement such a monitoring system to address a widespread issue of suboptimal dosing.
The panel led by Jamile Shammo, MD, reacts to results from a claims database study comparing the agent with ESAs.
The expert panel discussion led by Jamile Shammo, MD, also noted differences in cell line suppression by mutational profile.
Jamile Shammo, MD, leads a roundtable discussion on the effect of molecular data incorporation and goals in treatment.
Dr. David Swoboda discusses the importance of MDS World Awareness Day and what makes MDS unique compared to other diseases.
The expert panel led by Jamile Shammo, MD, tells how trial data and their clinical experiences inform their use of the agent.
The expert panel discusses current issues in the use of ESAs within MDS management.
In a roundtable discussion, an expert panel discussed how approval of luspatercept has affected frontline MDS treatment.
The expert panel describes how having two separate classification systems for MDS affects their clinical practices.
The expert panel discusses how to explain to patients the range of MDS severities and approach lower-risk disease.
The expert panel discusses molecular testing's current place in MDS evaluation and treatment decisions.
In a roundtable discussion, an expert panel describes recent trends in the classification and prognosis of MDS in the clinic.
In this video interview, Dr. Swoboda talks MDS highlights from ASH 2023, including the COMMANDS and IMerge trial.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.